Stable Expression of Adalimumab in Nicotiana tabacum

  • Tzvi Zvirin
  • Lena Magrisso
  • Amit Yaari
  • Oded Shoseyov
Original Paper
  • 60 Downloads

Abstract

Production of monoclonal antibodies and pharmaceutical proteins in transgenic plants has been the focus of many research efforts for close to 30 years. Use of plants as bioreactors reduces large-scale production costs and minimizes risk for human pathogens contamination. Stable nuclear transformation of the plant genome offers a clear advantage in agricultural protein production platforms, limited only by the number of hectares that can be cultivated. We report here, for the first time, successful and stable expression of adalimumab in transgenic Nicotiana tabacum plants. The plant-derived adalimumab proved fully active and was shown to rescue L929 cells from the in vitro lethal effect of rhTNFα just as effectively as commercially available CHO-derived adalimumab (Humira). These results indicate that agricultural biopharming is an efficient alternative to mammalian cell-based expression platforms for the large-scale production of recombinant antibodies.

Keywords

Plant-derived antibody Plant-made pharmaceuticals Adalimumab Humira TNF-α Nicotiana tabacum 

Notes

Acknowledgements

We thank Dr. Meirav Blanka for her help in the development of the quantitative ELISA and Dr. Yehudit Posen for critically reviewing this manuscript. This study was supported by the Minerva Center for bio-hybrid complex system.

Supplementary material

12033_2018_75_MOESM1_ESM.docx (181 kb)
Supplementary material 1 (DOCX 181 kb)

References

  1. 1.
    Stoger, E., Sack, M., Fischer, R., & Christou, P. (2002). Plantibodies: Applications, advantages and bottlenecks. Current Opinion in Biotechnology, 13, 161–166.  https://doi.org/10.1016/S0958-1669(02)00303-8.CrossRefGoogle Scholar
  2. 2.
    Schillberg, S., Twyman, R. M., & Fischer, R. (2005). Opportunities for recombinant antigen and antibody expression in transgenic plants technology assessment. Vaccine, 23, 1764–1769.  https://doi.org/10.1016/j.vaccine.2004.11.002.CrossRefGoogle Scholar
  3. 3.
    Fahad, S., Khan, F. A., Pandupuspitasari, N. S., et al. (2014). Recent developments in therapeutic protein expression technologies in plants. Biotechnology Letters, 37, 265–279.  https://doi.org/10.1007/s10529-014-1699-7.CrossRefGoogle Scholar
  4. 4.
    Fischer, R., Stoger, E., Schillberg, S., et al. (2004). Plant-based production of biopharmaceuticals. Current Opinion in Plant Biology, 7, 152–158.  https://doi.org/10.1016/j.pbi.2004.01.007.CrossRefGoogle Scholar
  5. 5.
    Hiatt, A., & Cafferkey, R. B. K. (1989). Production of antibodies in transgenic plants. Nature, 342, 76–78.CrossRefGoogle Scholar
  6. 6.
    Gomord, V., Chamberlain, P., Jefferis, R., & Faye, L. (2005). Biopharmaceutical production in plants: Problems, solutions and opportunities. Trends in Biotechnology, 23, 559–565.  https://doi.org/10.1016/j.tibtech.2005.09.003.CrossRefGoogle Scholar
  7. 7.
    Goldstein, D. A., & Thomas, J. A. (2004). Biopharmaceuticals derived from genetically modified plants. QJM: Monthly Journal of the Association of Physicians, 97, 705–716.  https://doi.org/10.1093/qjmed/hch121.CrossRefGoogle Scholar
  8. 8.
    Huang, Z., Phoolcharoen, W., Lai, H., et al. (2010). High-level rapid production of full-size monoclonal antibodies in plants by a single-vector DNA replicon system, 106, 9–17.  https://doi.org/10.1002/bit.22652.Google Scholar
  9. 9.
    Daniell, H., Streatfield, S. J., & Wycoff, K. (2001). Medical molecular farming: Production of antibodies, biopharmaceuticals and edible vaccines in plants. Trends in Plant Science, 6, 219.  https://doi.org/10.1016/S1360-1385(01)01922-7.CrossRefGoogle Scholar
  10. 10.
    Twyman, R. M., Stoger, E., Schillberg, S., et al. (2003). Molecular farming in plants: Host systems and expression technology. Trends in Biotechnology, 21, 570–578.  https://doi.org/10.1016/j.tibtech.2003.10.002.CrossRefGoogle Scholar
  11. 11.
    Sack, M., Hofbauer, A., Fischer, R., & Stoger, E. (2015). The increasing value of plant-made proteins. Current Opinion in Biotechnology, 32, 163–170.  https://doi.org/10.1016/j.copbio.2014.12.008.CrossRefGoogle Scholar
  12. 12.
    Liénard, D., Sourrouille, C., Gomord, V., & Faye, L. (2007). Pharming and transgenic plants. Biotechnology Annual Review, 13, 115–147.  https://doi.org/10.1016/S1387-2656(07)13006-4.CrossRefGoogle Scholar
  13. 13.
    Yusibov, V., Kushnir, N., & Streatfield, S. J. (2016). Antibody production in plants and green algae. Annual Review of Plant Biology, 67, 669–701.  https://doi.org/10.1146/annurev-arplant-043015-111812.CrossRefGoogle Scholar
  14. 14.
    Paul, M., Van, Dolleweerd C., Drake, P. M. W., et al. (2011). Future targets and aspirations. Molecular pharming. Human Vaccines.  https://doi.org/10.4161/HV.7.3.14456.Google Scholar
  15. 15.
    Fischer, R., Twyman, R. M., & Schillberg, S. (2003). Production of antibodies in plants and their use for global health. Vaccine, 21, 820–825.  https://doi.org/10.1016/S0264-410X(02)00607-2.CrossRefGoogle Scholar
  16. 16.
    Twyman, R. M., Schillberg, S., & Fischer, R. (2008). Production of therapeutic antibodies in plants. Medicinal Plant Biotechnology: From Basic Research to Industrial Applications.  https://doi.org/10.1002/9783527619771.ch14.Google Scholar
  17. 17.
    Goldstein, D. A., & Thomas, J. A. (2004). Review Biopharmaceuticals derived from genetically modified plants. QJM, 97, 705–716.  https://doi.org/10.1093/qjmed/hch121.CrossRefGoogle Scholar
  18. 18.
    Fischer, R., & Emans, N. (2000). Molecular farming of pharmaceutical proteins. Transgenic Research, 9, 279–299.  https://doi.org/10.1023/A:1008975123362.CrossRefGoogle Scholar
  19. 19.
    Westerhof, L. B., Wilbers, R. H. P., van Raaij, D. R., et al. (2014). Monomeric IgA can be produced in planta as efficient as IgG, yet receives different N-glycans. Plant Biotechnology Journal, 12, 1333–1342.  https://doi.org/10.1111/pbi.12251.CrossRefGoogle Scholar
  20. 20.
    Decker, T., & Gifford, G. E. (1987). Cell-associated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic Information about subscribing to The Journal of Immunology is online at: Mechanism of activated cytotoxic macrophages. Journal of Immunology, 138, 957–962.Google Scholar
  21. 21.
    Mitoma, H., Horiuchi, T., Tsukamoto, H., et al. (2008). Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor α-expressing cells: Comparison among infliximab, etanercept, and adalimumab. Arthritis and Rheumatism, 58, 1248–1257.  https://doi.org/10.1002/art.23447.CrossRefGoogle Scholar
  22. 22.
    Bazzoni, F., & Beutler, B. (1996). The tumor necrosis factor ligand and receptor families. The New England Journal Of Medicine, 334, 1717–1725.CrossRefGoogle Scholar
  23. 23.
    Committee for Proprietary Medicinal Products. (2004). Humira—European public assessment reports. Scientific discussion (pp. 1–25).Google Scholar
  24. 24.
    Shani, Z., Dekel, M., Tsabary, G., & Shoseyov, O. (1997). Cloning and characterization of elongation specific endo-1,4-β-glucanase (cel1) from Arabidopsis thaliana. Plant Molecular Biology, 34, 837–842.CrossRefGoogle Scholar
  25. 25.
    Grohs, B., Niu, Y., Veldhuis, L., et al. (2010). Plant-produced trastuzumab inhibits the growth of HER2 positive cancer cells. Journal of Agriculture and Food Chemistry.  https://doi.org/10.1021/jf102284f.Google Scholar
  26. 26.
    Ma, J. K. C., Drossard, J., Lewis, D., et al. (2015). Regulatory approval and a first-in-human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plants. Plant Biotechnology Journal, 13, 1106–1120.  https://doi.org/10.1111/pbi.12416.CrossRefGoogle Scholar
  27. 27.
    Wilken, L. R., & Nikolov, Z. L. (2012). Recovery and purification of plant-made recombinant proteins. Biotechnology Advances, 30, 419–433.  https://doi.org/10.1016/j.biotechadv.2011.07.020.CrossRefGoogle Scholar
  28. 28.
    Bouquin, T., Thomsen, M., Nielsen, L. K., et al. (2002). Human anti-Rhesus D IgG1 antibody produced in transgenic plants. Transgenic Research, 11, 115–122.  https://doi.org/10.1023/A:1015226418688.CrossRefGoogle Scholar
  29. 29.
    Aalberse, R. C., Akkerdaas, J. H., & Van Ree, R. (2001). Cross-reactivity of IgE antibodies to allergens. Allergy, 56, 478–490.  https://doi.org/10.1016/S0091-6749(97)70245-8.CrossRefGoogle Scholar
  30. 30.
    Bardor, M., Faveeuw, C., Fitchette, A.-C., et al. (2003). Immunoreactivity in mammals of two typical plant glyco-epitopes, core alpha(1,3)-fucose and core xylose. Glycobiology, 13, 427–434.  https://doi.org/10.1093/glycob/cwg024.CrossRefGoogle Scholar
  31. 31.
    Gomord, V. (2004). Production and glycosylation of plant-made pharmaceuticals: The antibodies as a challenge. Plant Biotechnology Journal, 2, 83–100.  https://doi.org/10.1111/j.1467-7652.2004.00062.x.CrossRefGoogle Scholar
  32. 32.
    Stein, H., Wilensky, M., Tsafrir, Y., et al. (2009). Production of bioactive, post-translationally modified, heterotrimeric, human recombinant type-I collagen in transgenic tobacco. Biomacromolecules, 3, 2640–2645.CrossRefGoogle Scholar
  33. 33.
    Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., et al. (1987). Protocols in molecular biology. New York, NY: Greene Publishing Associates and Wiley-Interscience John Wiley and Sons.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Tzvi Zvirin
    • 1
  • Lena Magrisso
    • 1
  • Amit Yaari
    • 1
  • Oded Shoseyov
    • 1
  1. 1.The Robert H. Smith Institute of Plant Sciences and Genetics in Agriculture, The Robert H. Smith Faculty of Agriculture, Food and EnvironmentThe Hebrew University of JerusalemRehovotIsrael

Personalised recommendations